Complete Test Bank for Pharmacology Clear and Simple: A Guide to Drug Classifications and Dosage Calculations, 4th Edition

TEST BANK u o




PHARMACOLOGY
CLEAR & SIMPLE:
u o u o




A Guide to Drug Classifications and Dosage Calculations
uo uo uo uo uo uo uo




3RD EDITION| By: Cynthia J. Watkins
uo uo uo uo uo




TEST BANK u o

,Test uoBank: uoPharmacology uoClear uoand uoSimple: uoA uoGuide uoto uoDrug
Classifications uoand uoDosage uoCalculations uo3rd uoEdition uoby uoCynthia uoJ. uoWatkins
uo




Table uoof uoContents:
Chapter uo1. uoHistory uoof uoPharmacology
Chapter uo2. uoBasics uoof uoPharmacology
Chapter uo3. uoPatient uoSafety uoin uoMedication uoAdministration
Chapter uo4. uoRegulations
Chapter uo5. uoPrescriptions uoand uoLabels
II. uoCalculations
Chapter uo6. uoBasic uoReview uoof
Mathematics uoChapter uo7. uoMeasurement
uo



uo Systems uoChapter uo8. uoDosage
uo Calculations
Chapter uo9. uoEnteral uoMedications uoand uoAdministration
Chapter uo10. uoParenteral uoMedications uoand uoAdministration
Chapter uo11. uoIntegumentary uoSystem uoMedications
Chapter uo12. uoMusculoskeletal uoSystem uoMedications
Chapter uo13. uoNervous uoSystem uoMedications
Chapter uo14. uoEye uoand uoEar uoMedications
Chapter uo15. uoEndocrine uoSystem uoMedications
Chapter uo16. uoCardiovascular uoSystem uoMedications
Chapter uo17. uoImmunological uoSystem uoMedications
Chapter uo18. uoPulmonary uoSystem uoMedications
Chapter uo19. uoGastrointestinal uoSystem uoMedications
Chapter uo20. uoReproductive uoand uoUrinary uoSystems uoMedications
Chapter uo21. uoHerbs, uoVitamins, uoand uoMinerals

,Chapter uo1. uoHistory uoof u o Pharmacology
Pharmacology uoClear uoand uoSimple- uoA uoGuide uoto uoDrug uoClassifications uoand uoDosage uoCalculations
uo3rd uoEdition uoWatkins uoTest uoBank




1. A uonurse uoworking uoin uoradiology uoadministers uoiodine uoto uoa uopatient uowho uois uohaving
uoacomputed uotomography uo(CT) uoscan. uoThe uonurse uoworking uoon uothe uooncology uounit

uoadministers uochemotherapy uoto uopatients uowho uohave uocancer. uoAt uothe uoPublic

uoHealthDepartment, uoa uonurse uoadministers uoa uomeasles-mumps-rubella uo(MMR) uovaccine

uoto uoa uo14-month-old uochild uoas uoa uoroutine uoimmunization. uoWhich uobranch uoof

uopharmacology uobest uodescribes uothe uoactions uoof uoall uothree uonurses?


A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology uois uothe uostudy uoof uothe uobiologic uoeffects uoof uochemicals. uoNurses uoare
uoinvolved uowith uoclinical uopharmacology uoor uopharmacotherapeutics, uowhich uois uoa

uobranch uoof uopharmacology uothat uodeals uowith uothe uouses uoof uodrugs uoto uotreat, uoprevent,

uoand uodiagnose uodisease. uoThe uoradiology uonurse uois uoadministering uoa uodrug uoto uohelp

uodiagnose uoa uodisease. uoThe uooncology uonurse uois uoadministering uoa uodrug uoto uohelp uotreata

uodisease. uoPharmacoeconomics uoincludes uoany uocosts uoinvolved uoin uodrug

uotherapy.Pharmacodynamics uoinvolves uohow uoa uodrug uoaffects uothe uobody uoand

uopharmacokinetics uois uohow uothe uobody uoacts uoon uothe uobody.




2. A uophysician uohas uoordered uointramuscular uo(IM) uoinjections uoof uomorphine, uoa
uonarcotic, uoevery uo4 uohours uoas uoneeded uofor uopain uoin uoa uomotor uovehicle

uoaccident u o victim. uoThe uonurse uois uoaware uothis uodrug uohas uoa uohigh uoabuse

uopotential. uoUnder uowhat uocategory uowould uomorphine uobe uoclassified?


A) Schedule uoI
B) Schedule uoII
C) Schedule uoIII
D) Schedule uoIV
Ans: B

, Feedback:
Narcotics uowith uoa uohigh uoabuse uopotential uoare uoclassified uoas uoSchedule uoII
uodrugs uobecause uoof uosevere uodependence uoliability. uoSchedule uoI uodrugs uohave

uohigh uoabuse uopotential u o and u o no uoaccepted uomedical u o use. u o Schedule u o III

u o drugs uohave u o a u o lesser uoabuse uopotential uothan uoII uoand uoan uoaccepted

uomedical uouse. uoSchedule uoIV uodrugs uohave uolow uoabuse uopotential uoand uolimited

uodependence uoliability.




3. When uoinvolved uoin uophase uoIII uodrug uoevaluation uostudies, uowhat
uoresponsibilities uowould uothe uonurse uohave?


A) Working uowith uo animals uowho uo are uo given uo experimental u o drugs
B) Choosing uoappropriate u o patients uo to uobe uo involved uo in uo the uodrug uo study
C) Monitoring uoand u o observing uopatients u o closely uo for uo adverse u o effects
D) Conducting uo research u o to uo determine u o effectiveness uo of uo the u o drug
Ans: C
Feedback:
Phase uoIII uostudies uoinvolve uouse uoof uoa uodrug uoin uoa uovast uoclinical uopopulation
uoin uowhich uopatients uoare uoasked uoto uorecord uoany uosymptoms uothey uoexperience

uowhile uotaking uothe uodrugs. uoNurses uomay uobe uoresponsible uofor uohelping

uocollect uoand uoanalyze uothe uoinformation uoto uobe uoshared uowith uothe uoFood uoand

uoDrug uoAdministration uo(FDA) uobut uowould uonot uoconduct uoresearch

uoindependently uobecause uonurses uodo uonot uoprescribe uomedications. uoUse uoof

uoanimals uoin uodrug uotesting uois uodone uoin uothe uopreclinical uotrials. uoSelect

uopatients uowho uoare uoinvolved uoin uophase uoII uostudies uoto uoparticipate uoin

uostudies uowhere uothe uoparticipants uohave uothe uodisease uothe uodrug uois uointended

uoto uotreat. uoThese uopatients uoare uomonitored uoclosely uofor uodrug uoaction uoand

uoadverse uoeffects. uoPhase uoI uostudies uoinvolve uohealthy uohuman uovolunteers

uowho uoare uousually uopaid uofor uotheir uoparticipation. uoNurses uomay uoobserve uofor

uoadverse uoeffects uoand uotoxicity.




4. What uoconcept uois uoconsidered uowhen uogeneric uodrugs uoare uosubstituted uofor
uobrand uoname uodrugs?


A) Bioavailability
B) Critical u o concentration
C) Distribution
D) Half-life
Ans: A
Feedback: